Pfizer shares jump 11% as profit soars 85% YoY in Q4FY25

In the past month, this pharma stock has surged by 18 percent

Shares of Pfizer jumped by as much as 11 percent to Rs 4,995 apiece on May 20 after the company posted a strong performance for the March quarter (Q4FY25).

In the past month, this pharma stock has surged by 18 percent, significantly outperforming the benchmark Nifty 50 index, which has risen by just 3 percent during the same period.

Pfizer’s profit skyrocketed by 85 percent year-on-year (YoY), rising to Rs 331 crore in Q4FY25 from Rs 179 crore in Q4FY24. Meanwhile, the company’s revenue from operations rose by 8.3 percent YoY, reaching Rs 591.9 crore in Q4FY25 compared to Rs 546.6 crore in Q4FY24.

On the operational front, earnings before interest, tax, depreciation and amortisation (Ebitda) increased by 20.1 percent on an annual basis, standing at Rs 227.5 crore for the March quarter of FY25, up from Rs 189.43 crore in the corresponding quarter of FY24. As a result, the Ebitda margin improved to 38.4 percent in Q4FY25, up from 34.7 percent in Q4FY24.

The company’s Board of Directors has recommended a final dividend of Rs 35 per equity share of Rs 10 each (equivalent to 350 percent), along with a special dividend of Rs 100 per equity share of Rs 10 each (1,000 percent), and an additional special dividend of Rs 30 per equity share of Rs 10 each (300 percent). These declarations come in celebration of Pfizer's 75th year of operations in India.

With a presence in over 125 countries, Pfizer plays a pivotal role in advancing global healthcare through its broad portfolio of innovative treatments and vaccines. In India, Pfizer maintains a strong footprint, including a cutting-edge manufacturing facility located in Goa, which supports both domestic needs and international distribution networks.